Skip to main content

Table 6 Predictive factors associated independently with the SVR to PEG-IFNα-RBV therapy in HCV-1 infected patients by multivariate logistic regression analysis

From: Association of MRC-1 and IL-28Bwith the treatment outcome of hepatitis C: a case control study

Parameter

Pvalue

OR (95% CI)

Diplotype§ (C − T/non-C − T)

< 0.0001*

2.96 (1.73, 5.06)

Gender (males/females)

0.4

0.77 (0.45, 1.34)

Age

0.01*

0.96 (0.94, 0.99)

BMI

0.05

0.91 (0.84, 1.00)

HCV-RNA levelδ (low/high)

0.07

7.41 (0.89, 62.0)

  1. Abbreviation: CI, confidence interval; BMI: body mass index.
  2. §The order of the SNPs comprising the IL28B and MRC1 diplotype was rs691005 and rs8099917.
  3. δLow HCV-RNA level: <100 KIU/ml by Amplicor-monitor assay. Odds ratios (OR) of having a SVR to PEG-IFNα-RBV therapy were calculated. P values less than 0.05 were considered statistically significant, and are denoted with an asterisk.